ClinicalTrials.gg

Program

adebrelimab

Also written as “SHR-1316”, “Adebrelimab” and “Adebrelimab Injection”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma · Pancreatic Neoplasms · Neoplasms · Breast Neoplasms, led by 2 companies.

Furthest: phase 3, since Oct 16, 201851 company-led studies, 40 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine4938 open or runningphase 3since Oct 16, 2018Apr 8, 2017Dec 2026phase 2 · NCT05482568
Hansoh Pharmaceutical Group22 open or runningphase 2since Aug 13, 2026Jul 3, 2025Mar 30, 2028phase 2 · NCT07824882

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 36 studies since Apr 8, 2017.

  1. Nov 13, 2025Phase 3 study in Advanced Biliary Tract CancerJiangsu HengRui Medicine · NCT07229625 · 604 planned · China
  2. Nov 14, 2025Phase 2 study in Lung NeoplasmsJiangsu HengRui Medicine · NCT07241767 · 200 planned · China
  3. Dec 9, 2025Phase 2 study in Locally Advanced or Metastatic Pancreatic Cancer WithJiangsu HengRui Medicine · NCT07296341 · 60 planned · China
  4. Jan 30, 2026Phase 3 study in Carcinoma, Transitional CellJiangsu HengRui Medicine · NCT07393542 · 453 planned · China
  5. Feb 25, 2026Phase 3 study in Locally Advanced Resectable Rectal CancerJiangsu HengRui Medicine · NCT07454720 · 165 planned · China
  6. Apr 3, 2026Phase 3 study in Locally Advanced Gastric or Gastroesophageal Junction CancerJiangsu HengRui Medicine · NCT07522151 · 874 planned · China
  7. Jun 25, 2026Phase 3 study in Triple Negative Breast NeoplasmsJiangsu HengRui Medicine · NCT07679360 · 1,000 planned · China
  8. Jul 2, 2026Phase 3 study in Carcinoma, HepatocellularJiangsu HengRui Medicine · NCT07691762 · 690 planned · China
  9. Jul 10, 2026Phase 2 study in Resectable Non-small Cell Lung CancerJiangsu HengRui Medicine · NCT07704645 · 180 planned · China
  10. Aug 13, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungPhase 2 reachedHansoh Pharmaceutical Group · NCT07824882 · 76 planned · China
  11. Aug 28, 2026Phase 2 study in Small Cell Lung CarcinomaJiangsu HengRui Medicine · NCT07798947 · 120 planned · China
  12. Sep 2, 20262 phase 2 studiesJiangsu HengRui Medicine · NCT07806058, NCT07863167
  13. Oct 19, 20262 phase 3 studiesJiangsu HengRui Medicine · NCT07896005, NCT07900789
  14. Oct 29, 2026Primary completion moved from 2031-04 to 2031-09Date moved laterphase 3 · +5 months · NCT07691762

Ahead

  1. Dec 2026Primary completion: phase 2 study in Advanced Malignant TumourJiangsu HengRui Medicine · NCT06915142
  2. Dec 2026Primary completion: phase 2 study in Advanced Non-small Cell Lung CancerJiangsu HengRui Medicine · NCT05482568
  3. Dec 30, 2026Primary completion: phase 2 study in Biliary Tract NeoplasmsJiangsu HengRui Medicine · NCT06465563
  4. Mar 2027Primary completion: phase 2 study in Squamous Cell Carcinoma of Head and NeckJiangsu HengRui Medicine · NCT07059221

TargetBeta

CD274 →read by rule
“An immunoglobulin G4 (IgG4), humanized monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), ”NCIt, by rule
“Programmed cell death 1 ligand 1 inhibitor”ChEMBL 37, by rule

Other programs on CD274

ProgramCompanyFurthest phaseStudies
durvalumabruleAstraZenecaphase 4102
pumitamigBioNTechphase 334
benmelstobartruleSino Biopharmaceuticalphase 333
retlirafusp alfaruleJiangsu HengRui Medicinephase 320
Anti-PD-L1 Antibody-drug Conjugate HLX43Fosun Pharmaphase 317
erfonrilimabruleAlphamab Oncologyphase 314
Anti-PD-L1/4-1BB Bispecific Antibody LBL-024rulenanjing-leads-biolabs-co-ltdphase 310
socazolimabruleLee's Pharmaceuticalphase 39
acasunlimabruleGenmabphase 36
sotiburafusp alfarulehuabo-biopharm-co-ltdphase 35
fetrastobart vedotinPfizerphase 32
HLX37Fosun Pharmaphase 32

Studies

All 51 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07900789Systemic Treatment-naïve Pancreatic Cancer · China3Not yet recruitingJiangsu HengRui MedicineNov 30, 2030825
NCT07896005Carcinoma, Non-Small-Cell Lung · China3Not yet recruitingJiangsu HengRui MedicineFeb 2031436
NCT07863167Carcinoma, Non-Small-Cell Lung · China2Not yet recruitingJiangsu HengRui MedicineDec 30, 2028660
NCT07806058Pancreatic Neoplasms · China2RecruitingJiangsu HengRui MedicineDec 31, 2028140
NCT07798947Small Cell Lung Carcinoma · China2RecruitingJiangsu HengRui MedicineDec 2028120
NCT07824882Carcinoma, Non-Small-Cell Lung · China2RecruitingHansoh Pharmaceutical GroupMar 30, 202876
NCT07704645Resectable Non-small Cell Lung Cancer · China2Not yet recruitingJiangsu HengRui MedicineJun 2028180
NCT07691762Carcinoma, Hepatocellular · China3Not yet recruitingJiangsu HengRui MedicineSep 2031690
NCT07679360Triple Negative Breast Neoplasms · China3RecruitingJiangsu HengRui MedicineDec 20301,000
NCT07522151Locally Advanced Gastric or Gastroesophageal Junction Cancer · China3RecruitingJiangsu HengRui MedicineDec 2029874
NCT07454720Locally Advanced Resectable Rectal Cancer · China3RecruitingJiangsu HengRui MedicineNov 2032165
NCT07393542Carcinoma, Transitional Cell · China3RecruitingJiangsu HengRui MedicineJan 31, 2028453
NCT07296341Locally Advanced or Metastatic Pancreatic Cancer With · China2RecruitingJiangsu HengRui MedicineOct 202760
NCT07241767Lung Neoplasms · China2RecruitingJiangsu HengRui MedicineNov 2027200
NCT07229625Advanced Biliary Tract Cancer · China3RecruitingJiangsu HengRui MedicineDec 2029604
NCT07168200Advanced Cervical Cancer · China3RecruitingJiangsu HengRui MedicineApr 2028720
NCT07118527Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma · China3RecruitingJiangsu HengRui MedicineOct 2030600
NCT07111832Triple Negative Breast Neoplasms · China3RecruitingJiangsu HengRui MedicineMar 2028400
NCT07073534Neoplasms · China2RecruitingJiangsu HengRui MedicineDec 2027203
NCT07063407Extensive Stage Small Cell Lung Cancer (ES-SCLC)1Not yet recruitingHansoh Pharmaceutical GroupApr 30, 202650
NCT07059221Squamous Cell Carcinoma of Head and Neck · China2RecruitingJiangsu HengRui MedicineMar 2027210
NCT07009457Widespread Small Cell Lung Cancer · China1Active, not recruitingJiangsu HengRui MedicineSep 202724
NCT06915142Advanced Malignant Tumour · China2RecruitingJiangsu HengRui MedicineDec 2026300
NCT06879145Muscular Invasive Bladder Cancer (MIBC) · China3RecruitingJiangsu HengRui MedicineDec 2031740
NCT06592625Untreated Early-stage or Locally Advanced Breast Cancer · China2Not yet recruitingJiangsu HengRui MedicineFeb 28, 202660
NCT06465563Biliary Tract Neoplasms · China2Active, not recruitingJiangsu HengRui MedicineDec 30, 202693
NCT06474468Esophageal Neoplasms · China2RecruitingJiangsu HengRui MedicineOct 2026148
NCT06417554Advanced Solid Tumors · China2RecruitingJiangsu HengRui MedicineDec 31, 203180
NCT06350006CLDN18.2-positive Advanced Solid Tumor · China1RecruitingJiangsu HengRui MedicineDec 30, 2027924
NCT06335355Non-squamous Non-small Cell Lung Cancer · China3Not yet recruitingJiangsu HengRui MedicineOct 2028401
NCT06247956Esophageal Squamous Cell Carcinoma · China2Active, not recruitingJiangsu HengRui MedicineDec 30, 2025153
NCT06237257Locally Advanced Cervical Cancer · China2Active, not recruitingJiangsu HengRui MedicineDec 202456
NCT06222879Breast Neoplasms · China2RecruitingJiangsu HengRui MedicineOct 31, 2026350
NCT06092268Advanced Solid Tumors2Not yet recruitingJiangsu HengRui MedicineDec 2025270
NCT05794477Advanced Solid Tumor · China2CompletedJiangsu HengRui MedicineAug 20, 202416
NCT05671822HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma · China2RecruitingJiangsu HengRui MedicineDec 2027258
NCT05482568Advanced Non-small Cell Lung Cancer · China2RecruitingJiangsu HengRui MedicineDec 2026324
NCT05444088Advanced Hepatocellular Carcinoma · China2RecruitingJiangsu HengRui MedicineJun 30, 2026129
NCT05416775Advanced Non-small Cell Lung Cancer · China2RecruitingJiangsu HengRui MedicineJun 30, 2026168
NCT05353361Breast Neoplasms · China2UNKNOWNJiangsu HengRui MedicineDec 31, 2025402
NCT05198817Advanced Malignant Tumors · China1UNKNOWNJiangsu HengRui MedicineJan 31, 2023240
NCT05082545Advanced Malignant Tumors · Australia1CompletedJiangsu HengRui MedicineJul 17, 202319
NCT04979390Neoplasms1UNKNOWNJiangsu HengRui MedicineFeb 10, 202215
NCT04691063Small Cell Lung Carcinoma · China3By invitationJiangsu HengRui MedicineMay 15, 2025486
NCT04316364Carcinoma, Non-Small-Cell Lung · China3RecruitingJiangsu HengRui MedicineApr 15, 2023537
NCT04041011Small Cell Lung Carcinoma · China1CompletedJiangsu HengRui MedicineApr 23, 202123
NCT03995472Advanced Malignancies · Australia, China1CompletedJiangsu HengRui MedicineJan 12, 202314
NCT03732508Advanced Esophageal Squamous Cell Cancer · China2UNKNOWNJiangsu HengRui MedicineNov 201930
NCT03711305Small Cell Lung Carcinoma · China3UNKNOWNJiangsu HengRui MedicineOct 2022462
NCT03474289Neoplasms · China1UNKNOWNJiangsu HengRui MedicineJan 30, 2019134
NCT03133247Advanced Solid Tumors · Australia1CompletedJiangsu HengRui MedicineApr 9, 201937

How it is read

Names in the registry

  • “SHR-1316”, 8 entries
  • “Adebrelimab”, 6 entries
  • “Adebrelimab Injection”, 4 entries
  • “adebrelimab + SHR-A2009”, 3 entries
  • “HRS-717 + HRS-4642+SHR-1316;”, 3 entries

Codes read as this program: SHR1316.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.